Lipo-C Blend
Status
No approved product. No FDA-approved labeling exists for lipotropic injection combinations, which are compounded preparations and are not reviewed by the FDA for safety or efficacy. No component holds an approved weight-loss indication.
What it is
A clinic blend of B vitamins and amino acids marketed for metabolism.
What published research measured
A compounded injectable combining lipotropic agents — typically methionine, inositol and choline — often with cyanocobalamin, marketed for fat loss. The individual components have defined roles in hepatic lipid metabolism, and choline deficiency causes hepatic steatosis, which is the kernel of legitimate biochemistry the product is built on. That is not the same as evidence that injecting them accelerates fat loss in people who are not deficient, and no randomized controlled trial supports the combination for weight reduction. No blend in this category has been studied as a blend. Trial evidence, where it exists, was generated on single agents given alone; no published study of the combination for interaction, additive adverse effects or altered pharmacokinetics was identified in the sources reviewed for this entry. Two practical consequences follow. A multi-compound vial is a compounded preparation, so the stability of each component in the presence of the others, and over the life of the vial, is generally unstudied. If a reaction occurs, multiple components make it difficult to attribute it to one of them, which is one reason clinical pharmacology usually introduces agents one at a time. The FDA has previously taken action against marketers of lipotropic injections for unsupported weight-loss claims.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.